Literature DB >> 21365252

Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.

Mathieu Hatt1, Dimitris Visvikis, Nidal M Albarghach, Florent Tixier, Olivier Pradier, Catherine Cheze-le Rest.   

Abstract

PURPOSE: (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) image-derived parameters, such as standardized uptake value (SUV), functional tumour length (TL) and tumour volume (TV) or total lesion glycolysis (TLG), may be useful for determining prognosis in patients with oesophageal carcinoma. The objectives of this work were to investigate the prognostic value of these indices in oesophageal cancer patients undergoing combined chemoradiotherapy treatment and the impact of TV delineation strategies.
METHODS: A total of 45 patients were retrospectively analysed. Tumours were delineated on pretreatment (18)F-FDG scans using adaptive threshold and automatic (fuzzy locally adaptive Bayesian, FLAB) methodologies. The maximum standardized uptake value (SUV(max)), SUV(peak), SUV(mean), TL, TV and TLG were computed. The prognostic value of each parameter for overall survival was investigated using Kaplan-Meier and Cox regression models for univariate and multivariate analyses, respectively.
RESULTS: Large differences were observed between methodologies (from -140 to +50% for TV). SUV measurements were not significant prognostic factors for overall survival, whereas TV, TL and TLG were, irrespective of the segmentation strategy. After multivariate analysis including standard tumour staging, only TV (p < 0.002) and TL (p = 0.042) determined using FLAB were independent prognostic factors.
CONCLUSION: Whereas no SUV measurement was a significant prognostic factor, TV, TL and TLG were significant prognostic factors for overall survival, irrespective of the delineation methodology. Only functional TV and TL derived using FLAB were independent prognostic factors, highlighting the need for accurate and robust PET tumour delineation tools for oncology applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21365252     DOI: 10.1007/s00259-011-1755-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  38 in total

1.  Prognostic value of the standardized uptake value in esophageal cancer.

Authors:  Henderik L van Westreenen; John T M Plukker; David C P Cobben; Carolien J M Verhoogt; Henk Groen; Pieter L Jager
Journal:  AJR Am J Roentgenol       Date:  2005-08       Impact factor: 3.959

2.  Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies.

Authors:  Linda M Velasquez; Ronald Boellaard; Georgia Kollia; Wendy Hayes; Otto S Hoekstra; Adriaan A Lammertsma; Susan M Galbraith
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

3.  Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.

Authors:  Johannes B Roedl; Mukesh G Harisinghani; Rivka R Colen; Alan J Fischman; Michael A Blake; Douglas J Mathisen; Peter R Mueller
Journal:  Ann Thorac Surg       Date:  2008-10       Impact factor: 4.330

4.  Evaluation of esophageal cancer by positron emission tomography.

Authors:  Shinji Himeno; Seiei Yasuda; Hideo Shimada; Tomoo Tajima; Hiroyasu Makuuchi
Journal:  Jpn J Clin Oncol       Date:  2002-09       Impact factor: 3.019

5.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

Authors:  Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg
Journal:  Clin Positron Imaging       Date:  1999-05

6.  Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET.

Authors:  Perrine Tylski; Simon Stute; Nicolas Grotus; Kaya Doyeux; Sébastien Hapdey; Isabelle Gardin; Bruno Vanderlinden; Irène Buvat
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

7.  Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study.

Authors:  Catherine Cheze-Le Rest; Jean-Philippe Metges; Pierre Teyton; Véronique Jestin-Le Tallec; P Lozac'h; A Volant; D Visvikis
Journal:  Nucl Med Commun       Date:  2008-07       Impact factor: 1.690

8.  Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.

Authors:  Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim
Journal:  Ann Surg Oncol       Date:  2009-10-14       Impact factor: 5.344

9.  Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma.

Authors:  Thomas Cazaentre; Franck Morschhauser; Maximilien Vermandel; Nacim Betrouni; Thierry Prangère; Marc Steinling; Damien Huglo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-30       Impact factor: 9.236

10.  Staging investigations for oesophageal cancer: a meta-analysis.

Authors:  E P M van Vliet; M H Heijenbrok-Kal; M G M Hunink; E J Kuipers; P D Siersema
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  51 in total

1.  Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.

Authors:  Mathieu Hatt; Adrien Le Pogam; Dimitris Visvikis; Olivier Pradier; Catherine Cheze Le Rest
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

Review 2.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

3.  The age of reason for FDG PET image-derived indices.

Authors:  Dimitris Visvikis; Mathieu Hatt; Florent Tixier; Catherine Cheze Le Rest
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-12       Impact factor: 9.236

4.  Variability of average SUV from several hottest voxels is lower than that of SUVmax and SUVpeak.

Authors:  E Laffon; F Lamare; H de Clermont; I A Burger; R Marthan
Journal:  Eur Radiol       Date:  2014-06-04       Impact factor: 5.315

5.  Autoclustering of Non-small Cell Lung Carcinoma Subtypes on (18)F-FDG PET Using Texture Analysis: A Preliminary Result.

Authors:  Seunggyun Ha; Hongyoon Choi; Gi Jeong Cheon; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-06-11

6.  Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Authors:  Hua-Xiang Xu; Tao Chen; Wen-Quan Wang; Chun-Tao Wu; Chen Liu; Jiang Long; Jin Xu; Ying-Jian Zhang; Run-Hao Chen; Liang Liu; Xian-Jun Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-13       Impact factor: 9.236

7.  The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).

Authors:  Odré Palie; Pierre Michel; Jean-François Ménard; Caroline Rousseau; Emmanuel Rio; Boumédiene Bridji; Ahmed Benyoucef; Marc-Etienne Meyer; Khadija Jalali; Stéphane Bardet; Che Mabubu M'vondo; Pierre Olivier; Guillaume Faure; Emmanuel Itti; Christian Diana; Claire Houzard; Françoise Mornex; Frederic Di Fiore; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-29       Impact factor: 9.236

8.  18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.

Authors:  Elena Elimova; Xuemei Wang; Elba Etchebehere; Hironori Shiozaki; Yusuke Shimodaira; Roopma Wadhwa; Venkatram Planjery; Nikolaos Charalampakis; Mariela A Blum; Wayne Hofstetter; Jeff H Lee; Brian R Weston; Manoop S Bhutani; Jane E Rogers; Dipen Maru; Heath D Skinner; Homer A Macapinlac; Jaffer A Ajani
Journal:  Eur J Cancer       Date:  2015-08-28       Impact factor: 9.162

9.  Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.

Authors:  Seung Hwan Moon; Su-Hee Cho; Lee Chun Park; Jun Ho Ji; Jong-Mu Sun; Jin Sock Ahn; Keunchil Park; Joon Young Choi; Myung-Ju Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-18       Impact factor: 9.236

10.  Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas.

Authors:  Xavier Cuenca; Christophe Hennequin; Elif Hindié; Sofia Rivera; Laetitia Vercellino; Valérie Baruch-Hennequin; Jean-Marc Gornet; Pierre Cattan; Mircea Chirica; Laurent Quéro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-01       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.